Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Mansoura University Children Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03721627CT.gov Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gaucher Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ledipasvir (this asset) | Mansoura University Children Hospital | Approved | BB · 64 |
| Taliglucerase Alfa | Protalix | P4 | A |
| Velaglucerase Alfa | Takeda | P4 | A |
| .Alpha.-D-Glucosyl-N-Acylsphingosine Glucohydrolase | Sanofi | P4 | A |
| Eliglustat | Peking Union Medical College Hospital | P3 | BBB |
| Cerezyme® / Imiglucerase | University Hospital, Clermont-Ferrand | P4 | BBB |
| Isofagomine | Amicus Therapeutics | P2 | BB |
| Sofosbuvir | Mansoura University Children Hospital | P4 | BB |
| isu302 | ISU Abxis Co., Ltd. | P3 | BB |
+20 more in the Gaucher Disease cohort
Other indications for Ledipasvir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis C Virus Infection | — | P4 | BBB · 77 |
| Chronic Hepatitis C Virus Infection | — | P3 | BB · 68 |
| Liver Disorder | — | P4 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ledipasvir in Gaucher Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ledipasvir-gaucher-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →